<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35248703</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1769-7123</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>173</Volume>
            <Issue>4-5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Season>May-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>Research in microbiology</Title>
          <ISOAbbreviation>Res Microbiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pal depletion results in hypervesiculation and affects cell morphology and outer-membrane lipid asymmetry in bordetellae.</ArticleTitle>
        <Pagination>
          <StartPage>103937</StartPage>
          <MedlinePgn>103937</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.resmic.2022.103937</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0923-2508(22)00018-3</ELocationID>
        <Abstract>
          <AbstractText>Current vaccines against Bordetella pertussis do not prevent colonization and transmission of the bacteria, and vaccine-induced immunity wanes rapidly. Besides, efficacy of vaccines for Bordetella bronchiseptica remains unclear. Novel vaccines could be based on outer-membrane vesicles (OMVs), but vesiculation of bordetellae needs to be increased for cost-effective vaccine production. Here, we focused on increasing OMV production by reducing the anchoring of the outer membrane to the peptidoglycan layer. Inactivation of rmpM, tolR, and pal failed, presumably because their products are essential in bordetellae. Conditional pal mutants were constructed, which were hypervesiculating under Pal-depletion conditions. SDS-PAGE and Western blot analyses showed that the protein composition of OMVs produced under Pal-depletion conditions resembled that of the outer membrane but differed from that of OMVs released by the wild type. Pal depletion affected the cell morphology and appeared to increase the amounts of cell-surface-exposed phospholipids, possibly reflecting a role for the Tol-Pal system in retrograde phospholipid transport. We also identified additional lipoproteins in bordetellae with a putative peptidoglycan-anchoring domain. However, their inactivation did not influence OMV production. We conclude that the conditional pal mutants could be valuable for the development of OMV-based vaccines.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>de Jonge</LastName>
            <ForeName>Eline F</ForeName>
            <Initials>EF</Initials>
            <AffiliationInfo>
              <Affiliation>Section Molecular Microbiology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, the Netherlands; Institute of Biomembranes, Utrecht University, Utrecht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Boxtel</LastName>
            <ForeName>Ria</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Section Molecular Microbiology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balhuizen</LastName>
            <ForeName>Melanie D</ForeName>
            <Initials>MD</Initials>
            <AffiliationInfo>
              <Affiliation>Section Molecular Host Defence, Division Infectious Diseases &amp; Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haagsman</LastName>
            <ForeName>Henk P</ForeName>
            <Initials>HP</Initials>
            <AffiliationInfo>
              <Affiliation>Section Molecular Host Defence, Division Infectious Diseases &amp; Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tommassen</LastName>
            <ForeName>Jan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Section Molecular Microbiology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, the Netherlands; Institute of Biomembranes, Utrecht University, Utrecht, the Netherlands. Electronic address: j.p.m.tommassen@uu.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Res Microbiol</MedlineTA>
        <NlmUniqueID>8907468</NlmUniqueID>
        <ISSNLinking>0923-2508</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001425">Bacterial Outer Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008563">Membrane Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010457">Peptidoglycan</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001425" MajorTopicYN="N">Bacterial Outer Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001884" MajorTopicYN="Y">Bordetella</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008563" MajorTopicYN="N">Membrane Lipids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010457" MajorTopicYN="Y">Peptidoglycan</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bordetella</Keyword>
        <Keyword MajorTopicYN="N">Outer-membrane vesicles</Keyword>
        <Keyword MajorTopicYN="N">Peptidoglycan-associated lipoprotein</Keyword>
        <Keyword MajorTopicYN="N">RmpM</Keyword>
        <Keyword MajorTopicYN="N">Tol-Pal system</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare no conflict of interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>20</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35248703</ArticleId>
        <ArticleId IdType="doi">10.1016/j.resmic.2022.103937</ArticleId>
        <ArticleId IdType="pii">S0923-2508(22)00018-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
